Histogenics Stock Fundamentals
Histogenics fundamentals help investors to digest information that contributes to Histogenics' financial success or failures. It also enables traders to predict the movement of Histogenics Stock. The fundamental analysis module provides a way to measure Histogenics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Histogenics stock.
Histogenics |
Histogenics Company Current Valuation Analysis
Histogenics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Histogenics Current Valuation | 18.12 M |
Most of Histogenics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Histogenics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Histogenics has a Current Valuation of 18.12 M. This is 99.87% lower than that of the Healthcare sector and 99.61% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.89% higher than that of the company.
Histogenics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Histogenics's current stock value. Our valuation model uses many indicators to compare Histogenics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Histogenics competition to find correlations between indicators driving Histogenics's intrinsic value. More Info.Histogenics is one of the top stocks in return on equity category among related companies. It is one of the top stocks in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Histogenics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Histogenics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Histogenics' earnings, one of the primary drivers of an investment's value.Histogenics Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Histogenics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Histogenics could also be used in its relative valuation, which is a method of valuing Histogenics by comparing valuation metrics of similar companies.Histogenics is currently under evaluation in current valuation category among related companies.
Histogenics Fundamentals
| Return On Equity | 2.0E-4 | |||
| Return On Asset | -1.36 | |||
| Current Valuation | 18.12 M | |||
| Shares Outstanding | 94.6 M | |||
| Shares Owned By Insiders | 6.44 % | |||
| Shares Owned By Institutions | 10.94 % | |||
| Number Of Shares Shorted | 7.35 M | |||
| Price To Earning | (1.49) X | |||
| Price To Book | 53.33 X | |||
| Revenue | 26 K | |||
| Gross Profit | 23.26 K | |||
| EBITDA | (19.79 M) | |||
| Net Income | (3.02 M) | |||
| Cash And Equivalents | 2.79 M | |||
| Cash Per Share | 0.03 X | |||
| Total Debt | 1.25 M | |||
| Debt To Equity | 58.30 % | |||
| Current Ratio | 4.05 X | |||
| Book Value Per Share | (59.59) X | |||
| Cash Flow From Operations | (25.4 M) | |||
| Short Ratio | 2.02 X | |||
| Earnings Per Share | (0.36) X | |||
| Number Of Employees | 49 | |||
| Beta | 3.94 | |||
| Market Capitalization | 255.42 K | |||
| Total Asset | 36.79 M | |||
| Retained Earnings | (106.55 M) | |||
| Working Capital | 24.88 M | |||
| Current Asset | 31.24 M | |||
| Current Liabilities | 6.36 M | |||
| Z Score | -2.8 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Histogenics information on this page should be used as a complementary analysis to other Histogenics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Histogenics Stock
If you are still planning to invest in Histogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Histogenics' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |